ClinicalTrials.gg
Active, not recruitingNCT04469712Updated Feb 6, 2025

Non-randomized Prospective Comparison Between SASI Bipartition and RYGB

An observational study in Obesity, Morbid, Metabolic Syndrome and Bariatric Surgery Candidate, sponsored by Aleris Hospital. Active, not recruiting at 1 site in Norway. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-02-06.

Sponsored by Aleris Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
280
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Obesity, Morbid with a site in Norway — 22 open to participants now, 26 under way, none of them phase 3. Obesity, Morbid · Norway.

Planned enrollment
Largest of 30
280 · median 12
Started
2020
the only one that year
Observational
30 of 51
21 open now
Primary completion
2027-07
later than 23 of 25 live
Registered
49th of 51
by date
Lead sponsor
1 of 51
Aleris Hospital

Among the 51 studies in Obesity, Morbid with a site in Norway, this one has the largest planned enrollment of the 30 observational ones that give a count, is the only one that started in 2020, is one of 30 observational ones, reaches primary completion later than 23 of the 25 other live ones, and was the 49th registered.

Obesity, Morbid

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

Browse Obesity, Morbid studies →

Open to participants now

22 of the 51 studies in Obesity, Morbid with a site in Norway are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Obesity, Morbid with a site in Norway, or all of them as a file.
02

Study summary

The main aim of this project is to assess the safety and efficiency of the SASI Bipartition.

Read the detailed description

The Roux-en-Y Gastric Bypass (RYGB) is the procedure of choice in morbid obesity with metabolic disorders in most of the reference centers. Recent data describes the SASI Bipartition as being as efficient on weight loss and co-morbidities as the RYGB, with the advantage of being less technically difficult and less morbidity. In order to draw definite conclusions regarding the procedure, larger series with longer follow-up are necessary.

Patients with BMI over 40, or with BMI over 35 with comorbidities are offered SASI Bipartition with 300 cm common limb or standard RYGB. Follow up is performed through visits at 3, 12, 24, 36, 48, and 60 months after surgery.

Results on weight loss, comorbidities resolution, complications, and need of supplements are registered.

03

Conditions studied

  • Obesity, Morbid
  • Metabolic Syndrome
  • Bariatric Surgery Candidate
  • Postoperative Complications

Keywords

  • Gastric Bypass,
  • SASI Bipartition
  • Weight loss
  • GERD
  • Internal Hernia
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients approved for bariatric surgery at Bariatric Clinic, Aleris Hospital, Norway

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Morbid obesity with ≥ 40 kg/m2 or BMI ≥ 35 kg/m2 associated with one or more co-morbidities (type 2 diabetes, arterial hypertension, sleep apnea, dyslipidemia, arthritis)

Exclusion criteria

Exclusion Criteria:

  • Mental diseases
  • Drug addiction
  • Alcoholic
  • Pregnancy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
280 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes
Biospecimen retention
Samples without dna

Groups and cohorts

  • SASI Bipartition

    Subjects submitted to SASI Bipartition

    Procedure: SASI Bipartition

  • Roux-en-Y gastric bypass

    Subjects submitted to gastric bypass

    Procedure: Gastric bypass

Interventions

  • ProcedureSASI Bipartition

    SASI Bipartition is performed with a sleeve gastrectomy over a 32 French gastric bougie and a 300 cm common limb. Side-to-side gastroileostomy with a diameter of approximately 2.5 cm at the anterior part of antrum, 6 cm proximal to pylorus.

    Also known as: Single-anastomosis Sleeve Ileal Bypass

  • ProcedureGastric bypass

    A small gastric pouch (15 mL) is created, and the jejunum brought up as an antecolic and antegastric fashion. Routine limb lengths were 150 cm for the alimentary limb and 60 cm for the bilio-pancreatic limb. Both mesenteric defects are closed with the Endohernia® stapler.

    Also known as: Roux-en-Y gastric bypass

06

What researchers measure

Primary outcomes

  1. Weight change

    Measured as percent of Excess Weight Loss (%EWL) using the following formula: ((weight at each study visit - initial weight) / (initial weight - ideal weight)) X 100

    Time frame: 3 to 60 months after surgery

  2. Waist size change

    Waist size (in cm)

    Time frame: 3 to 60 months after surgery

  3. Medical and surgical complication

    According to Clavien-Dindo classification

    Time frame: 3 to 60 months after surgery

  4. Operative time

    Expressed in minutes

    Time frame: During surgery

  5. Hemoglobin

    Measurement of Hemoglobin will explore the nutritional status of patients. Results will be expressed in g/l

    Time frame: before surgery up to 60 months after surgery

  6. Albumin

    Measurement of albumin will explore the nutritional status of patients. Results will be expressed in g/l

    Time frame: before surgery up to 60 months after surgery

  7. Ferritin

    Measurement of ferritin will explore the nutritional status of patients. Results will be expressed in microg/l

    Time frame: before surgery up to 60 months after surgery

  8. Iron

    Measurement of iron will explore the nutritional status of patients. Results will be expressed in micromol/l

    Time frame: before surgery up to 60 months after surgery

  9. Parathyroid hormone (PTH)

    Measurement of PTH will explore the nutritional status of patients. Results will be expressed in pmol/L

    Time frame: before surgery up to 60 months after surgery

  10. Vitamin B12

    Measurement of vitamin B12 will explore the nutritional status of patients. Results will be expressed in pmol/l

    Time frame: before surgery up to 60 months after surgery

  11. Vitamin D

    Measurement of vitamin D will explore the nutritional status of patients. Results will be expressed in nmol/l

    Time frame: before surgery up to 60 months after surgery

Secondary outcomes

  1. Fasting glycemia

    Measurement of fasting glycemia will explore the Metabolic efficiency of surgery. Results will be expressed in mmol/l

    Time frame: before surgery up to 60 months after surgery

  2. HbA1c

    Measurement of HbA1c will explore the Metabolic efficiency of surgery. Results will be expressed in %

    Time frame: before surgery up to 60 months after surgery

  3. Triglycerides

    Measurement of triglycerides will explore the Metabolic of surgery. Results will be expressed in mmol/l

    Time frame: before surgery up to 60 months after surgery

  4. Cholesterol

    Measurement of cholesterol will explore the Metabolic efficiency of surgery. Results will be expressed in mmol/l

    Time frame: before surgery up to 60 months after surgery

  5. HDL

    Measurement of HDL will explore the Metabolic efficiency of surgery. Results will be expressed in mmol/l

    Time frame: before surgery up to 60 months after surgery

  6. LDL

    Measurement of LDL will explore the Metabolic efficiency of surgery. Results will be expressed in mmol/l

    Time frame: before surgery up to 60 months after surgery

  7. Antidiabetic drugs

    Evolution of antidiabetic drugs will explore the Metabolic efficiency of surgery. This outcome will be expressed in terms of increase, decrease, discontinuation or restart of treatment.

    Time frame: 3 to 60 months after surgery

  8. Antilipidemic drugs

    Evolution of antilipidemic drugs will explore the Metabolic efficiency of surgery. This outcome will be expressed in terms of increase, decrease, discontinuation or restart of treatment.

    Time frame: 3 to 60 months after surgery

  9. Antihypertensive drugs

    Evolution of antihypertensive drugs will explore the Metabolic efficiency of surgery. This outcome will be expressed in terms of increase, decrease, discontinuation or restart of treatment.

    Time frame: 3 to 60 months after surgery

  10. Use of Continuous Positive Airway Pressure for Obstructive Sleep Apnea (OSA)

    Evolution of the use of Continuous Positive Airway Pressure will explore the Metabolic efficiency of surgery. This outcome will be expressed in terms of persistence or not of OSA.

    Time frame: 3 to 60 months after surgery

07

Study locations

1 site
  • Aleris Hospital
    Oslo, 0264, Norway
08

References and documents

Publications

  • Aghajani E, Nergaard BJ, Leifson BG, Hedenbro J, Gislason H. The mesenteric defects in laparoscopic Roux-en-Y gastric bypass: 5 years follow-up of non-closure versus closure using the stapler technique. Surg Endosc. 2017 Sep;31(9):3743-3748. doi: 10.1007/s00464-017-5415-2. Epub 2017 Feb 15. PubMed 28205037 ↗
  • Santoro S, Castro LC, Velhote MC, Malzoni CE, Klajner S, Castro LP, Lacombe A, Santo MA. Sleeve gastrectomy with transit bipartition: a potent intervention for metabolic syndrome and obesity. Ann Surg. 2012 Jul;256(1):104-10. doi: 10.1097/SLA.0b013e31825370c0. PubMed 22609843 ↗
  • Mahdy T, Al Wahedi A, Schou C. Efficacy of single anastomosis sleeve ileal (SASI) bypass for type-2 diabetic morbid obese patients: Gastric bipartition, a novel metabolic surgery procedure: A retrospective cohort study. Int J Surg. 2016 Oct;34:28-34. doi: 10.1016/j.ijsu.2016.08.018. Epub 2016 Aug 19. PubMed 27545956 ↗
  • Mui WL, Lee DW, Lam KK. Laparoscopic sleeve gastrectomy with loop bipartition: A novel metabolic operation in treating obese type II diabetes mellitus. Int J Surg Case Rep. 2014;5(2):56-8. doi: 10.1016/j.ijscr.2013.12.002. Epub 2013 Dec 10. PubMed 24441436 ↗
  • Shah K, Johnny Nergard B, Stray Frazier K, Geir Leifsson B, Aghajani E, Gislason H. Long-term effects of laparoscopic Roux-en-Y gastric bypass on metabolic syndrome in patients with morbid obesity. Surg Obes Relat Dis. 2016 Sep-Oct;12(8):1449-1456. doi: 10.1016/j.soard.2016.03.017. Epub 2016 Mar 19. PubMed 27387692 ↗

Individual participant data

Plan to share: Undecided — The results of the study will be published in a scientific journal.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2020 (actual). Primary completion is estimated for Jul 2027, 83 months after the start.

Of 138 non-industry observational studies under Obesity, Morbid, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 132. This study's planned 83 months is above that.

Counting every sponsor, half of 139 studies reached it within 46 months; a quarter within 16 and three quarters within 132.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2020
First posted
Jul 14, 2020
StartActual
Aug 1, 2020
Primary completionEst.
Jul 1, 2027
CompletionEst.
Aug 1, 2027
Last update
Feb 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04469712
Lead sponsor
Aleris Hospital
Responsible party
Ebrahim Aghajani (Gastrointestinal Surgeon, PhD, Principal investigator, Aleris Hospital) — Principal investigator
First posted
Jul 14, 2020
Start date
Aug 1, 2020
Primary completion
Jul 1, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Feb 6, 2025

Study contacts

Ebrahim Aghajani, PhD
principal investigator · Aleris Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion